ABSTRACT: Targeting LRRK2 for Drug Discovery
PD Therapeutics 2009: Poster Abstracts
Steven P Braithwaite, Wyeth
01 Oct 2009
Mutations in Leucine Rich repeat Kinase 2 (LRRK2) lead to a form of autosomal dominant Parkinson’s Disease (PD) with symptoms and pathological hallmarks that are similar to sporadic forms of ... 
ABSTRACT: Evaluation of the Striatum-enriched Genes CalDAG-GEF1 and CalDAG-GEF2 as Targets for the Treatment and Prevention of L-DOPA Induced Dyskinesia
PD Therapeutics 2009: Poster Abstracts
Ann Graybiel, MIT
17 Sep 2009
The most widely prescribed therapy for Parkinson’s disease is levodopa (L-DOPA), which allows patients to regain motor control. However, many patients develop adverse reactions to L-DOPA, ... 
ABSTRACT: The Parkinson’s Progression Markers Initiative: A Prospective Biomarkers Study
PD Therapeutics 2009: Poster Abstracts
Mark Frasier, MJFF
17 Sep 2009
Parkinson’s disease (PD) interventional trials rely predominantly on clinical outcomes that often vary within subjects and are not consistent across subjects. Reliable and well-validated ... 
ABSTRACT: BAC-Engineered Alpha-Synuclein Transgenic Rats
PD Therapeutics 2009: Poster Abstracts
Chenjian Li, Cornell
17 Sep 2009
A severe and unfortunate roadblock in Parkinson’s disease (PD) research is that to date no genetic mammalian models have recapitulated well the cardinal PD pathology of dopaminergic neuronal ... 
ABSTRACT: PD Online Research: A professional collaborative community for rapid-fire problem-solving in Parkinson’s disease science
PD Therapeutics 2009: Poster Abstracts
Holli Kawadler, MJFF, et al.
16 Sep 2009
PD Online Research (PDOR) is a collaborative community for technical discussion and problem-solving in Parkinson’s disease science, powered by he Michael J. Fox Foundation for ... 
ABSTRACT: Hsp90 as a Target for Neuroprotective Agents in Parkinson’s Disease
PD Therapeutics 2009: Poster Abstracts
Pamela J McLean, MGH
16 Sep 2009
Cell death caused by alpha-synuclein is thought to play a central role in the pathogenesis of Parkinson’s disease. We have previously shown that a class of compounds called Hsp90 inhibitors can ... 
ABSTRACT: Brain and Body Donation Program of the Arizona Parkinson’s Disease Consortium
PD Therapeutics 2009: Poster Abstracts
Thomas G Beach, Sun Health
16 Sep 2009
Recognizing that increased knowledge of the clinicopathological correlates of Parkinson’s disease is critical to understanding the progression of the disease and developing novel treatment ...